Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?

Purpose To compare the level of parenchymal and portal venous enhancement in the portal venous phase (PVP) in cirrhotic patients undergoing gadoxetate disodium- and gadobenate dimeglumine-enhanced MRI. Methods In this retrospective study, 84 cirrhotic patients (mean age +/- SD: 66 +/- 13 years) who underwent contrast-enhanced MRI with both gadoxetate disodium and gadobenate dimeglumine between 2012 and 2018 were included. Two readers measured signal intensities of hepatic parenchyma, portal vein and psoas muscle on precontrast and PVP. Relative enhancement (RE), image contrast, and portal vein-to-liver contrast difference were calculated. Intraindividual differences were compared with the Wilcoxon signed rank-sum test and inter-reader differences with the intraclass correlation coefficient (ICC). Results In PVP, gadoxetate disodium provided lower RE than gadobenate dimeglumine (Reader 1: 42.4 +/- 44.6 vs. 56.1 +/- 58.8, p = 0.044; Reader 2: 42.4 +/- 42.9 vs. 57.7 +/- 60.5, p = 0.027;), lower image contrast (Reader 1: 0.27 +/- 0.11 vs. 0.35 +/- 0.11, respectively; p < 0.001; Reader 2: 0.29 +/- 0.10 vs. 0.37 +/- 0.07, respectively; p < 0.001), and lower portal vein-to-liver contrast difference (Reader 1: 0.89 +/- 0.39 vs. 1.42 +/- 0.90, p < 0.001; Reader 2: 0.95 +/- 0.40 vs. 1.28 +/- 0.37, p < 0.001). ICC was 0.94, 0.79, and 0.69 for RE, image contrast, and portal vein-to-liver contrast difference, respectively. Conclusion In cirrhotic patients, gadoxetate disodium yielded lower enhancement of the hepatic parenchyma and lower contrast of the portal vein than gadobenate dimeglumine in PVP.